Although the clinical importance of heart failure with preserved ejection fraction (HFpEF), which makes up half of heart failure, has been extensively explored, most therapeutic regimens, including nitric oxide (NO) donors, lack therapeutic benefit 1-12 . Here we report that neuronal nitric oxide synthase (nNOS, also known as NOS1) induces HFpEF by Snitrosylation of histone deacetylase 2 (HDAC2). HFpEF animal models-SAUNA (SAlty drinking water/Unilateral Nephrectomy/Aldosterone) 13,14 and mild transverse aortic constriction (TAC) mice 14,15 -showed increased nNOS expression and NO production, which resulted in the S-nitrosylation of HDAC2. HFpEF was alleviated in S-nitrosylation-dead HDAC2 knock-in mice. Pharmacologic intervention by either nNOS inhibition or HDAC2 denitrosylation attenuated HFpEF. Our observations are the first to demonstrate a completely new mechanistic aspect in HFpEF, which may provide a novel therapeutic approach to HFpEF. In addition, our results provide evidence for why conventional NO-enhancement trials have not been effective for improving HFpEF.
Introduction
Heart failure refers to an insufficient circulation of blood to peripheral organs. The wellknown type is systolic heart failure, the characteristics of which are a loss of effective myocardium for contraction 16, 17 . In recent decades, in part due to the prevalence of metabolic diseases such as diabetes, the patient population with HFpEF has grown, with a parallel increase in the clinical and social burdens of this disease 5, 6, 8, 10 . To date, 50% of total heart failure is regarded as HFpEF 6 . Unfortunately, none of the therapies that have been proven effective for heart failure with reduced ejection fraction (HFrEF) have been proven beneficial for increasing the survival rate of patients with HFpEF 2, 11, 12, [18] [19] [20] [21] . It is surprising that even NO donors, which are potent vasodilators, do not have any benefit in the treatment of HFpEF 2,11 , and this raises fundamental questions as whether our strategy of replenishing NO is appropriate. Indeed, in the current work, we propose that NOS/NO-mediated nitrosylation of protein may worsen HFpEF, suggesting critical reconsideration of the therapeutic effect of NO.
Results
Although no perfect mouse model for HFpEF is available 14 , we applied the SAUNA model (Methods, Fig. 1a ), which is known to be most similar to human HFpEF 13, 14 . At 30 days after initiation of the protocol, we measured cardiac function: parameters of exercise capacity such as ejection fraction (EF), early diastole (E), and mitral valve annulus movement (E'); and performance on a rotarod treadmill test (Methods). Systolic function was well conserved in the SAUNA group. However, the E/E' ratio was aberrantly increased (Fig. 1b , Extended Data Fig. 1a ). Furthermore, locomotive activities were impaired in SAUNA mice (Extended Data Fig. 1c ). Thus, we confirmed that the SAUNA model successfully induced HFpEF. As an alternative model, mild TAC (Methods) was introduced. Four weeks after mild TAC, we assessed cardiac function (Extended Data Fig. 1b, 1c, 1d ). We found that mild TAC could also induce HFpEF in less than 1 month.
To delineate the mechanism of HFpEF, we measured posttranslational modifications of proteins in both mouse models. Among the posttranslational modifications tested, protein Snitrosylation was significantly increased (Fig. 1d ), whereas no notable alterations in acetylation, methylation, or phosphorylation were observed (Extended Data Fig. 1e, 1f, 1g ). NO can be generated by three nitric oxide synthases: nNOS, iNOS2 (NOS2), and eNOS (NOS3) 22 . To understand the source of the NO, we measured transcript amounts of nNOS, iNOS, or eNOS by quantitative real-time PCR. Both nNOS and iNOS were dramatically increased in mild TAC mice, whereas only nNOS was activated in the SAUNA model ( Fig.   1e, 1f ). We confirmed that nNOS was predominantly increased in cardiomyocytes isolated from SAUNA-treated mice (Methods) ( Fig. 1g ).
Several pharmacologic agents specifically inhibit nNOS [23] [24] [25] [26] [27] [28] . Thus, to confirm the involvement of nNOS, we used N(ω)-propyl-L-arginine (NPLA) 28 in our HFpEF models.
Injection of NPLA every other day (Methods) improved both diastolic dysfunction and exercise capacity ( Fig. 1h, 1i , 1j) Next, we looked for nNOS-specific S-nitrosylation targets in the heart by using a biotinswitching assay 29 (Methods). Infection of H9c2 cells with adenovirus nNOS-HA generated de novo S-nitrosylation ( Fig. 2a ). By mass spectrometry, we identified that nNOS S-nitrosylated of Hdac2 and Gapdh ( Fig. 2a ). Incubation of S-nitrosoglutathione (GSNO), a nonselective NO donor, with heart lysates increased S-nitrosylation of both proteins (Extended Data Fig.   2a ). S-Nitrosylation of Hdac2 and Gapdh was further confirmed by western blot (Fig. 2b , Extended Data Fig. 2b, 2c ).
To test whether SAUNA stresses induced S-nitrosylation of Hdac2, we performed the biotin-switching assay with SAUNA heart lysates and observed that S-nitrosylation of Hdac2 was significantly increased (Fig. 2c, 2d ). S-Nitrosylation of Hdac2 was also observed in the mild TAC model (Extended Data Fig. 2d ). S-Nitrosylation of Hdac2 was nearly completely abolished in SAUNA mice with NPLA administration ( Fig. 2e ). nNOS is mainly located in the cytoplasmic membrane, whereas HDAC2 is tethered in the nucleus. Hence, we assumed that nNOS 'indirectly' S-nitrosylates Hdac2 by transferring NO from membranous nNOS to nuclear HDAC2. Kornberg et al 30 reported that GAPDH may work as a shuttling mediator of NO after its S-nitrosylation at Cys150 and after redistribution in the cell. In our experimental models, Gapdh was also S-nitrosylated by nNOS ( Fig. 2a ), which then resulted in its nuclear redistribution ( Fig. 2f ). It is also noteworthy that physical interaction between Gapdh and Hdac2 increased in the presence of nNOS ( Fig. 2g ). When a nonselective nitrosylation-inducer, GSNO, was incubated with heart lysates, Gapdh also physically interacted with Hdac2 (Extended Data Fig. 2e ).
Two cysteine residues, Cys262 and Cys274, are known to be responsible for Snitrosylation of HDAC2 31 . These residues are highly conserved throughout species (Fig. 3a ).
We generated S-nitrosylation-resistant mutant mice by gene knocking-in technology and substituting those two cysteines with alanines (hereafter, HDAC2 2CA). We could not observe S-nitrosylation of HDAC2 in HDAC2 2CA mouse embryonic fibroblasts even in the presence of adenovirus nNOS-HA ( Fig. 3b ).
We then applied the SAUNA model to HDAC2 2CA mice. SAUNA failed to exaggerate diastolic dysfunction in HDAC2 2CA mice. The aberrant increase in the E/E' ratio seen in wild type was not observed in HDAC2 2CA (Fig. 3c ). HDAC2 2CA mice also did not develop SAUNA-induced impairment of exercise tolerance (Fig. 3d ). As expected, systolic function was well conserved in HDAC2 2CA mice even in SAUNA stresses (Extended Data Fig. 3a ). SAUNA-induced HDAC2 S-nitrosylation was not detected in HDAC2 2CA hearts ( Fig. 3e ). Mild TAC also failed to induce diastolic dysfunction in HDAC2 2CA mice (Extended Data Fig. 3b ). Thus, we concluded that HDAC2 2CA mice can tolerate HFpEF.
We next questioned whether S-nitrosylation affects HDAC2 function in HFpEF by measuring HDAC2 activity (Methods). The deacetylase activity of HDAC2 from heart lysates was not changed by GSNO-induced nitrosylation (Extended Data Fig. 3c ). Thus, rather than its deacetylase activity, other functions of HDAC2 such as intracellular localization or alterations in complex formation may contribute to the development of HFpEF. This remains to be clarified.
Heretofore, we delineated the roles of nNOS in association with HDAC2 C262/C274 Snitrosylation in the development of HFpEF. Hence, we questioned whether pharmacologic intervention to reduce the nitrosylation of HDAC2 could also alleviate HFpEF. As reported previously 32 , we observed that NRF2 (also known as NFE2L2) can denitrosylate HDAC2 in cardiac cells. Adenovirus NRF2 significantly activated its target gene, Glutathione S-Transferase Alpha 3 (GSTA3), in H9c2 cells (Extended Data Fig. 4a, 4b ). Adenovirus nNOS-HA infection in H9c2 cells successfully induced HDAC2 S-nitrosylation, which was attenuated by infection of adenovirus NRF2 (Fig. 4a ).
To test the effect of NRF2-induced denitrosylation on HFpEF, we designed an AAV9-NRF2 delivery scheme ( Fig. 4b ). Direct cardiac injection of AAV9-NRF2 ameliorated diastolic dysfunction in SAUNA mice ( Fig. 4c ) without any significant changes in systolic function (Extended Data Fig. 4c ). Locomotor intolerance was also improved by cardiac overexpression of NRF2 ( Fig. 4d ). As expected, S-nitrosylation of HDAC2 was notably attenuated in the AAV9-NRF2 injection group (Fig. 4e ). AAV9-NRF2 infection was confirmed by transcription amounts of the target gene, GSTA3 (Extended Data Fig. 4d ).
Although the specific mechanism remains unclear, dimethyl fumarate (DMF) has been reported to induce NRF2 transcription 33 . We tested whether DMF could alleviate the HFpEF phenotype (Methods). Daily intake of DMF activated NRF2 and subsequently induced GSTA3 (Extended Data Fig. 4e, 4f ). Like AAV9-NRF2, HDAC2 S-nitrosylation was not observed in DMF-administered mice (Fig. 4f ). DMF also improved both diastolic dysfunction ( Fig. 4g ) and exercise tolerance ( Fig. 4h ), which suggests DMF as a novel therapeutic strategy for HFpEF.
To study whether S-nitrosylation of HDAC2 is also involved in HFrEF, we induced severe TAC in HDAC2 2CA mice or wild type littermates (Methods) and measured survival for 15 weeks. Interestingly, HDAC2 2CA mice showed no survival benefit compared with their wild type littermates in this model (Extended Data Fig. 4g ). Severe impairment of EF, a surrogate indicator of HFrEF, was also observed as either in the wild type mice or in DMFadministered mice (Extended Data Fig. 4h ). Similarly, DMF did not improve the survival rate of wild type mice exposed to severe TAC. These findings suggested that nitrosative stress specifically induces HFpEF rather than general heart failure.
No established regimens are currently available for the patients with HFpEF 3,6,10,17,34 .
Whereas NO has beneficial effects like vasodilation and reduction of afterload in HFrEF, NO donors are not at all effective for improving the survival of HFpEF 2,11 . Although preliminary, our new findings that NO-mediated nitrosylation provokes HFpEF may explain why NO donors do not work in the clinical setting. Our study is not the only work to suggest NO as an inducer of HFpEF; indeed, a recent report also implied NOS/NO-mediated nitrosylation of protein in the development of HFpEF 35 . Thus, it is very likely that S-nitrosylation of key proteins may lead the scientific world to revisit NO as a potential therapeutic target of HFpEF. Of note, unlike in HFrEF, however, inhibition of NOS or removal of S-nitrosylation could be considered in HFpEF.
Methods

Antibodies
Antibodies used were as follows: mouse monoclonal anti-HDAC2 (Abcam, 1:5,000, 12169), rabbit polyclonal anti-HDAC2 (Invitrogen, 1:1,000, 51-5100), mouse monoclonal GAPDH (Bio-Rad, 1:1,000, VMA00046), rabbit polyclonal anti-GAPDH (Bio-Rad, 1:1,000, VPA00187), and mouse monoclonal anti-HA (Sigma, 1:30,000, H9658).
Animal model
The use of animal experiments for disease models was approved by the Chonnam National 
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). The left ventricle was collected after 10 minutes' digestion and cut into small pieces. Further digestion was performed with gentle stirring for 10 minutes. The cells were allowed to stand briefly for large parts to settle and supernatants were filtered by use of a 100-mm pre-cell strainer. The filtered cells were plated on culture dishes for 2 hours to remove cardiac fibroblasts.
Biotin-switching assay
Protein S-nitrosylation was measured after biotin-switching 29 Protein sequences were not changed except for two targeted cysteines (CGADSLSGDRLGC to AGADSLSGDRLGA). Genotype was determined by T7E1 (NEB, M0302). Direct Sanger sequencing of PCR products was requested to further confirm the genotype of the homozygote. The oligomer set for genotyping was as follows: sense: 5'-TGCTGTCAATTTTCCCATGA-3', antisense: 5'-AGAGTTTGGCATCGAGTTGG-3'.
Histone deacetylase activity assay
A commercial kit (HDAC-Glo TM 2 Assays, Promega, G9590) was used to measure HDAC2 activity. Heart lysates were prepared with 1% NP buffer without EDTA to avoid zinc chelation. Fifty micrograms of heart lysates were mixed with HDAC2 assay substrate and 
Rotarod treadmill test
The locomotor tolerance of mice was measured by using a rotarod system (ENV-577M, Med Associate Inc). Mice were pre-adapted to the rod at a fixed speed of 10 rpm for 5 minutes before measurement. Mice were placed on the round rod (35-mm diameter) with a continuous acceleration from 4 to 40 rpm by 1 rpm per 5 seconds. Motor ability was determined as the time of falling off or passive rolling with grasp rod, up to 5 minutes. The best latency time of 3 tests was used for the study. Time interval between each trial was 30 minutes.
Statistics
Statistical significance was analyzed with PASW Statistics 25 (SPSS, IBM corp). For two independent groups, two-tailed unpaired Student's t-test was applied after checking for a normal distribution. In the case of more than two groups, one-way analysis of variance was used. Bonferroni's post hoc test was applied for multiple comparisons when equal variance was assumed by use of Levene statistics, whereas the Dunnett T3 test was used in case of unequal variance. Survival rate was visualized and calculated by use of Prism 8.0 (GraphPad). Significance was determined at values of p < 0.05. Robust S-nitrosylation of HDAC2 by SAUNA stress was completed blocked by NPLA injection. f, g, Transnitrosylation of GAPDH to HDAC2. Nitrosative stress derived by nNOS infection induced nuclear targeting of GAPDH after S-nitrosylation (Extended Data Fig. 2b) (f). Physical interaction between HDAC2 and GAPDH was increased in the presence of nitric oxide (g). Elevation of E/E' was attenuated (g) and exercise ability was also improved by DMF (h). c, d, g, h, ANOVA with Tukey's post hoc. ### and *** mean p<0.0001, ## indicates p<0.001.
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